Non-small cell lung cancer treatment-related bone marrow toxicities.
A major consequence of administering increasingly aggressive therapies (chemotherapy with or without radiation therapy) in the treatment of non-small cell lung cancer is the adverse effects on the bone marrow that may lead to neutropenia, thrombocytopenia, and/or anemia. Myelosuppression or bone marrow toxicity may also lead to dose reduction of chemotherapy and/or treatment delays in both chemotherapy and radiation therapy, diminishing the efficacy of therapy in the curative setting. In this setting, the use of hematopoietic growth factors may thus be beneficial.
Ettinger
David S
DS
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231-1000, USA.
D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001853:Bone Marrow / Q000187:drug effects* / Q000528:radiation effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D003115:Colony-Stimulating Factors / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology; D011832:Radiation Injuries / Q000188:drug therapy / Q000517:prevention & control; D011878:Radiotherapy / Q000009:adverse effects; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology
D000970:Antineoplastic Agents; D003115:Colony-Stimulating Factors